English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

A bstract   Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect (CHD) attributable to multifactorial molecular underpinnings. Multiple genetic loci have been implicated to increase the risk of disease, yet genotype‐phenotype relationships remain poorly defined. Whole genome sequencing complemented by cardiac phenotype from five individuals in an HLHS‐affected family enabled the identification of  NOTCH1  as a prioritized candidate gene linked to CHD in three individuals with mutant allele burden significantly impairing Notch signaling in the HLHS‐affected proband. To better understand a mechanistic basis through which  NOTCH1  contributes to heart development, human induced pluripotent stem cells (hiPSCs) were created from the HLHS‐affected parent‐proband triad and differentiated into cardiovascular cell lineages for molecular characterization. HLHS‐affected hiPSCs exhibited a deficiency in Notch signaling pathway components and a diminished capacity to generate hiPSC‐cardiomyocytes. Optimization of conditions to procure HLHS‐hiPSC‐cardiomyocytes led to an approach that compensated for dysregulated nitric oxide (NO)‐dependent Notch signaling in the earliest specification stages. Augmentation of HLHS‐hiPSCs with small molecules stimulating NO signaling in the first 4 days of differentiation provided a cardiomyocyte yield equivalent to the parental hiPSCs. No discernable differences in calcium dynamics were observed between the bioengineered cardiomyocytes derived from the proband and the parents. We conclude that in vitro modeling with HLHS‐hiPSCs bearing  NOTCH1  mutations facilitated the discovery of a NO‐dependent signaling component essential for cardiovascular cell lineage specification. Potentiation of NO signaling with small therapeutic molecules restored cardiogenesis in vitro and may identify a potential therapeutic target for patients affected by functionally compromised  NOTCH1  variants. S tem  C ells   2017;35:1106–1119

stem cells

NOTCH1 ‐Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient‐Specific Phenotypes Detected in Bioengineered Cardiogenesis